Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-486-0 | CAS number: 102687-65-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Additional toxicological data
Administrative data
- Endpoint:
- additional toxicological information
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted under GLP conditions using methodology that is well accepted by organization responsible for fluorochemicals
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Cardiac sensitization is considered to have occurred if the response to epinephrine is enhanced following administration of the test substance.
- GLP compliance:
- yes
Test material
- Test material form:
- gas under pressure: liquefied gas
Constituent 1
Results and discussion
Any other information on results incl. tables
CLINICAL OBSERVATIONS AND SURVIVAL
All animals survived to the end of the study. After exposure to 50,000 ppm, vocalization during exposure, injected sclera and excessive salivation were noted in animal nos. 4935 and 4936. Tremors and reddened gums were noted for animal no. 4935 after exposure to 50,000 ppm, and convulsions were noted for animal no. 4936. These were the only 2 animals exposed to 50,000 ppm. After exposure to 35,000 ppm, tremors, injected sclera, reddened ears, excessive salivation and salivation-related findings (wet clear material and white frothy material around the mouth) were observed. These findings were considered test article-related due to the number of incidences. There were no other test article-related clinical findings. All other observations were limited to single animals, were not noted in a dose-related manner and/or were common findings for laboratory dogs of this age and breed.
BODY WEIGHTS
Body weights were collected for determination of doses only and were not analyzed for test article effects. Body weights ranged from 7.4 to 10.1 kg on the days of dosing.
ELECTROCARDIOGRAPHIC EXAMINATIONS
After exposure to 25,000 and 35,000 ppm, there were no signs of cardiac sensitization. Animal nos. 4938 and 4935 were not challenged with epinephrine following exposure to 35,000 ppm; background noise on the ECG precluded complete characterization of the potential cardiac sensitization response following administration of 35,000 ppm. Following the initiation of exposure to 50,000 ppm, animal no. 4935 exhibited tremors and animal no. 4936 exhibited convulsions. Only animal no. 4935 received any challenge doses of epinephrine (2 and 4 μg/kg), but the ECG data could not be evaluated due to artifacts and noise from the tremors. Therefore, the potential cardiac sensitization response following administration of 50,000 ppm could not be evaluated.
Applicant's summary and conclusion
- Conclusions:
- There was no evidence of cardiac sensitization to epinephrine in beagle dogs following inhalation exposure to the test substance at a concentration of 25000 ppm (2.5% or 132750 mg/m3). The cardiac sensitization potential following exposure to 35000 ppm (3.5% or 185850 mg/m3) and 50000 ppm (5.0% or 265500 mg/m3) could not be definitively evaluated due to the presence of tremors during exposure. Clinical findings of tremors, injected sclera and excessive salivation were observed at exposure levels of 35000 and 50000 ppm. Vocalization during exposure, reddened gums and convulsions were also noted following exposure to 50000 ppm, and evidence of salivation and reddened ears were noted after exposure to 35000 ppm.
- Executive summary:
Test substance was administered via muzzle-only inhalation exposure as acute exposures (gas) at concentrations of 2.5%, 3.5% and 5.0% (25000, 35000 and 50000 ppm, respectively). One group of 6 male dogs was used on this study with a minimum of 48 hours between exposure concentrations for each animal. Each dog served as its own control. Baseline response to the epinephrine challenge doses were collected 3 days prior to exposure to the test gas. For the 25000 and 35000 ppm groups, animals were administered predetermined increasing doses of epinephrine (2, 4, 6 and 8 µg/kg) as bolus injections (approximately 0.1 ml/sec) via an appropriate vein beginning approximately 5 minutes following exposure to the test article. Epinephrine challenge bolus injections were administered a minimum of 3 minutes apart or until the electrocardiogram (ECG) of the animal returned to its normal baseline rhythm. For the 50000 ppm group, 2 animals were exposed to the test article; however, due to behavioral responses displayed by the animals, exposure was terminated and no other animals were exposed at 50000 ppm. Only 1 of the animals exposed to 50000 ppm was administered epinephrine after exposure, and cardiac data following epinephrine challenge were not evaluated at this exposure level. Following the final exposure, all dogs were returned to the stock colony. The animals were observed twice daily for mortality and moribundity. Detailed physical examinations were performed and individual body weights were recorded approximately weekly during the pretest period, at randomization and on exposure days. Electrocardiographic data were recorded continuously throughout the pre-exposure period, exposure to the test gas and throughout administration of the challenge epinephrine dose (total of approximately 33 minutes).
There were no test substance-related deaths. After exposure to the test substance at a concentration of 50000 ppm, vocalization during exposure, injected sclera, excessive salivation, tremors, convulsions and/or reddened gums were noted. After exposure to 35000 ppm, tremors, injected sclera, reddened ears and excessive salivation and salivation-related findings were observed. There were no signs of cardiac sensitization in the animals challenged with epinephrine after exposure to 25000 and 35000 ppm of test substance. However, the presence of ECG noise in 2 animals following administration of 35000 ppm precluded complete characterization of the potential cardiac sensitization response at this exposure level. Following the initiation of exposure to 50000 ppm, two animals exhibited severe clinical findings (including tremors and/or convulsions), and only one of these animals was administered epinephrine after exposure; therefore, cardiac data following epinephrine challenge were not evaluated at 50000 ppm. In conclusion, in beagle dogs exposed to the test substance by inhalation, clinical findings of tremors, injected sclera and excessive salivation were observed at exposure levels of 35,000 and 50,000 ppm. Vocalization during exposure, reddened gums and convulsions were also noted following exposure to 50,000 ppm test substance, and evidence of salivation and reddened ears were noted after exposure to 35,000 ppm. There was no evidence of cardiac sensitization following exposure to 25,000 ppm (2.5%); the cardiac sensitization potential following exposure to 35,000 and 50,000 ppm (3.5% and 5.0%, respectively) could not be definitively evaluated due to the presence of tremors during exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies